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Abstract
Background: In a previous report, we hypothesized that responses to placebo were high in child and adolescent depression
because of specific psychopathological factors associated with youth major depression. The purpose of this study was to
compare the placebo response rates in pharmacological trials for major depressive disorder (MDD), obsessive compulsive
disorder (OCD) and other anxiety disorders (AD-non-OCD).
Methodology and Principal Findings: We reviewed the literature relevant to the use of psychotropic medication in children
and adolescents with internalized disorders, restricting our review to double-blind studies including a placebo arm. Placebo
response rates were pooled and compared according to diagnosis (MDD vs. OCD vs. AD-non-OCD), age (adolescent vs.
child), and date of publication. From 1972 to 2007, we found 23 trials that evaluated the efficacy of psychotropic medication
(mainly non-tricyclic antidepressants) involving youth with MDD, 7 pertaining to youth with OCD, and 10 pertaining to
youth with other anxiety disorders (N=2533 patients in placebo arms). As hypothesized, the placebo response rate was
significantly higher in studies on MDD, than in those examining OCD and AD-non-OCD (49.6% [range: 17–90%] vs. 31%
[range: 4–41%] vs. 39.6% [range: 9–53], respectively, ANOVA F=7.1, p=0.002). Children showed a higher stable placebo
response within all three diagnoses than adolescents, though this difference was not significant. Finally, no significant
effects were found with respect to the year of publication.
Conclusion: MDD in children and adolescents appears to be more responsive to placebo than other internalized conditions,
which highlights differential psychopathology.
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Introduction
Child and adolescent depression has been a public health
concern for some time because of its high implication in suicidal
acts and youth morbidity [1,2]. During the 1980s, the arrival of
the selective serotonin reuptake inhibitors (SSRIs), which are
associated with far fewer side effects than tricyclics or monoamine
oxidase inhibitors, was viewed as an important step in the
treatment of affective disorders, first in adults, and then in children
and adolescents. In the early 1990s, SSRI use in children and
adolescents increased rapidly in developed countries, sometimes to
a higher proportion than the prevalence rate of depression in this
age range [3]. However, placebo-controlled trials rarely demon-
strated the superiority of non-tricyclic antidepressants over placebo
mainly because of high placebo response rates, which make the
establishment of drug efficacy difficult. Treatment effects must be
substantial to be differentiated from placebo. The establishment of
SSRI efficacy was easier in child and adolescent obsessive
compulsive disorder (OCD) [4,5] and anxiety disorders (AD-
nonOCD) [6].
In a previous report [7], we hypothesized that the response to
placebo was high in child and adolescent depression because of
specific psychopathological factors associated with youth MDD
that promote psychotherapeutic effects in pharmacological trials.
This hypothesis was based on several points. First, MDD in
children and adolescents is not identical to that in adults or young
adults [8,9]. In particular, early risk factor profiles of adolescent
depression are very different from those of young adult depression
[9]. Additionally, the establishment of a therapeutic alliance is a
primary objective in any care-giving with a child or adolescent,
and it should be formed with both the child and his or her parents
[10]. Therapeutic alliance is a familiar concept for pediatric or
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treatment resistance in child and adolescent depression (for a
review, see Emslie et al, 2000 [11]) are very similar to the risk
factors associated with poor compliance in the field of pediatric
pharmacology in general (for a review, see Hack et al, 2001 [12]).
These include past history of poor compliance [13,14], family
dysfunction or poor parent-child communication [15,16], short
doctor’s appointments, parents’ dissatisfaction with the doctor, and
negative side-effects [13]. When a patient is included in a
pharmacological trial, he or she cannot be representative of all
depressed youths from a therapeutic alliance care perspective,
since we have to obtain informed consent from both the child (or
adolescent) and the parents prior to enrollment. Thus, the
inclusion of a patient in a trial implies some basic level of therapeutic
alliance. This then may lead to a better prognosis in terms of follow-
up,andmayleadtoaninflationofestimatesofthesizeoftheplacebo
effect, regardless of the treatment given. Third, psychotherapies,
such as interpersonal psychotherapy [17,18], cognitive and behav-
ioral therapy [19,20], family therapies [19,20], and psychodynamic
therapies [21], provide effective treatment for child and adolescent
depression. During a pharmacological trial, the clinician meets with
a child or adolescent each week, shows an interest in their life,
expresses concern about the impact of treatment, inquires about the
patient’s current situation, answers his or her questions, and so forth.
This implies for the patient, whether intended or not, the beginning
of a psychotherapeutic process with the clinician. The placebo effect
response may thus be partially due to the child being involved in an
unintentional psychotherapeutic dynamic, irrespective of the
orientation of the clinician. In pharmaceutical trials, the placebo
condition is used to control for non-specific effects of treatment. This
effectmayoccurwithotherinternalizeddisordersaswell,butmaybe
more pronounced in depression.
Whether the placebo response rate in MDD is similar to that of
other internalized conditions has not been systematically explored.
Given that many double-blind placebo-controlled studies have
been conducted in the last 25 years on internalized disorders, we
aimed to compare the placebo response rates in pharmacological
trials for major depressive disorder (MDD), obsessive compulsive
disorder (OCD), and other anxiety disorders (AD-non-OCD) using
response rates in all placebo arms. As it has been shown that the
time of research publication [22–24] and patient age may be
important in determining the placebo response [25], these factors
were also specifically explored.
Methods
Searching
We searched the Medline database for articles describing
randomised, placebo-controlled trials of medication for children
and adolescents diagnosed with MDD, OCD, and AD-non-OCD.
Searches included combinations of the following keywords: Major
depression, obsessive compulsive disorder and anxiety disorder and/or
children/adolescents and/or placebo-controlled. In addition, references
from identified articles and reviews on the same conditions were
examined. In particular, recent meta-analyses and reviews that
explored the relationship between non-tricyclic antidepressants
and suicide were of particular interest, given that some included
unpublished trials and detailed response rates according to age
[6,7,26–31].
Selection and validity assessment
Using these methods, we found 70 publications between
January 1972 and October 2007. Exclusion criteria were: (1)
cross-over design; (2) no indication of the number of responders in
either the original report or the available reviews; (3) fewer than 10
individuals in the placebo arms; (4) lack of placebo arms; (5) no
randomisation; (6) no double-blind evaluation of response; (7) trial
on post-traumatic stress disorder; and (8) data already reported
elsewhere. The quality of published trial reports for which data
were available was rated by DC using Detsky et al.’s [32] short
version criteria that includes items related to randomisation,
blindness, inclusion/exclusion criteria, outcome measures, treat-
ment description, and statistical analysis. For each report,
individual items were summed and divided by the total number
of applicable items to produce a total score ranging from 0 (poor
quality) to 1 (high quality) [6].
Data extraction and study characteristics
Two co-authors (DC and ED) independently extracted the
relevant data from the original selected reports and reviews.
Table 1 lists all of the published controlled randomized trials of
psychotropic medications that were included in the current
analysis. All placebo arms were included in a database for
statistical analysis.
Quantitative data synthesis
Response rates were compared between groups using ANOVA.
The assumption of homogeneity of variance was assessed with the
Barlett test. The assumption of normality was assessed with the
Shapiro-Wilk test. Then an analysis of variance weighted by the
number of subjects included in placebo arms was applied for
comparison of response rates according to diagnosis (MDD, OCD,
and AD-non-OCD). Given that analyses were performed across
studies, we kept each trial’s definition of responders as indicated in
table 1. The same analyses were conducted on a subgroup of studies
that used the CGI as either a primary or secondary variable
(responder=CGI#2). When available in the original publication or
in the review and meta-analyses listed earlier, data for children
(,12 years) and adolescents ($12 years) were distinguished and
compared using a Student’s t-test. Finally, the effect of the date of
study publication wasexamined using Spearmanrank correlation (r)
between year of publication and response to placebo.
Results
Among the 70 studies (N=5894 patients in total), we found 23
trials that evaluated the efficacy of psychotropic medication (mainly
non-tricyclicantidepressants)involvingyouthwithMDD,7onyouth
with OCD, and 10 on youth with other anxiety disorders (figure 1).
All together, the studies included 2533 patients in placebo arms
(N=1528 in MDD, N=371 in OCD, N=634 in AD-non-OCD).
Thirty studies were excluded from the analysis because of cross-over
(or other) design [33–40], non-dichotomized definition of responders
or absence of specific data [41–43], placebo arms with fewer than 10
patients [44–46], data reported elsewhere or re-analysis of previous
report [25,47–53], or lack of placebo arm [54–59]. Finally, Berstein
and colleagues’ studies [16,60] were excluded because all patients
had AD comorbid with MDD.
Figure 2 summarizes the placebo response rates according to
diagnosis. The assumption of homogeneity of variance was
assessed with the Barlett test, yielding a p value of 0.384. The
assumption of normality was assessed with the Shapiro-Wilk test,
which yielded p values of 0.65, 0.77, and 0.15 for MDD, OCD,
and AD-non-OCD, respectively. Given that it was not possible to
reject the hypothesis of the normality of residuals, a weighted
ANOVA was applied. As hypothesized, the placebo response rate
was significantly higher in studies on MDD when compared to
OCD and AD-non-OCD (F=7.1, df=2, p=0.002). Pooled
Placebo Response in Youth
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Study Q N (age) Duration Drug Definition of Responders
Placebo
Responders
Drug.
placebo
a
Major Depressive Disorder
Kramer, Feiguine 1981 [67] 0.67 20 (13–18) 6 weeks Amitryptiline Authors-scale 6/10 (60%) No
Preskorn et al. 1987 [68] 0.64 22 (6–12) 6 weeks Imipramine CGI 3/12 (25%) No
Puig-Antich et al. 1987 [69] 0.77 53 (prepub) 5 weeks Imipramine KSADdep/anhedonia#2 15/22 (68%) No
Hugues et al. 1990 [70] 0.5 31 (6–12) 6 weeks Imipramine CDRS 50% 7/14 (50%) No
Geller et al. 1990 [71] 0.6 31 (12–17) 8 weeks Nortryptiline CDRS,25% 4/19 (21%) No
Geller et al. 1992 [72] 0.89 50 (6–12) 8 weeks Nortryptiline CDRS#20 5/24 (17%) No
Kutcher et al. 1994* [73] 0.7 42 (15–19) 6 weeks Desipramine HDRS 50% 9/25 (36%) No
Kye et al. 1996 [74] 0.77 31 (12–18) 6 weeks Amitryptiline HDRS 50% 11/13 (90%) No
Emslie et al. 1997 [75] 0.97 96 (8–18) 8 weeks Fluoxetine CGI#2 or CDRS 30% 16/48 (33%) Yes
Birmaher et al. 1998 [76] 0.73 27 (13–17) 10 weeks Amitryptiline HDRS 50% 11/14 (79%) No
Klein et al. 1998 [77] 0.83 45 (13–18) 6 weeks Desipramine CGI#2 9/18 (50%) No
Milin et al. 2000** [78] 0.97 286 (13–18) 12 weeks Paroxetine MADRS 50% 53/91 (58%) No
Keller et al. 2001 [79] 0.85 275 (13–17) 8 weeks Paroxetine HDRS,8 or 50% 48/87 (55%) No
Emslie et al. 2002 [80] 0.89 219 (8–18) 8 weeks Fluoxetine CDRS30% 54/101 (54%) No
Wagner et al. 2003 [81] 0.93 376 (6–17) 10 weeks Sertraline CDRS 40% 105/179(59%) Yes
b
March et al. 2004 [82] 1 439 (12–17) 12 weeks Fluoxetine CGI#2 39/112 (35%) Yes
Wagner et al. 2004 [83] 0.67 174 (7–17) 8 weeks Citalopram CDRS#28 20/85 (24%) No
Emslie et al. 2006 [84] 0.97 206 (7–17) 8 weeks Paroxetine CGI#2 46/100 (46%) No
VonKnorring et al. 2006 [85] 0.5 244 (13–18) 12 weeks Citalopram KSADdep/anhedonia#2 47/77 (61%) No
Wagner et al. 2006 [86] 0.67 268 (6–17) 8 weeks Escitalopram CGI#2 69/132 (52%) No
Emslie et al. 2007 [87] 0.8 367 (7–17) 8 weeks Venlafaxine CDRS 30% 99/165 (60%) Yes
b
FDA: CN104-141 2007 [88] ND 206 (12–17) 8 weeks Nefazodone CGI#2 42/95 (44%) No
FDA: 003-045 2007 [89] ND 259 (7–17) 8 weeks Mirtazapine CGI#2 42/85 (49%) No
Obsessive Compulsive Disorder
DeVeaugh et al. 1992 [90] 0.79 60 (10–17) 8 weeks Clomipramine CGI#2 5/29 (17%) Yes
March et al. 1998 [91] 0.86 189 (6–17) 12 weeks Sertraline CYBOCS 25% 35/95 (37%) Yes
Geller et al. 2001 [92] 0.92 103 (6–17) 13 weeks Fluoxetine CYBOCS 40% 8/32 (25%) Yes
Riddle et al. 2001 [93] 0.86 120 (8–17) 10 weeks Fluvoxamine CYBOCS 25% 17/63 (27%) No
Liebowitz et al. 2002 [94] 0.72 43 (8–17) 8 weeks Fluoxetine CGI#2 7/22 (32%) No
Geller et al. 2004 [95] 0.96 207 (7–17) 10 weeks Paroxetine CYBOCS 25% 42/102 (41%) Yes
POTS 2004 [96] 1 112 (7–17) 12 weeks Sertraline CYBOCS,10 1/28 (4%) Yes
Non-Obsessive-Compulsive Anxiety Disorder
Gittelman-Klein 1973 [97] 0.86 35 (6–15) 6 weeks Imipramine School attendance 9/19 (47%) No
Berney et al. 1981 [98] 0.73 46 (9–15) 12 weeks Clomipramine CGI#2 10/19 (53%) No
Klein et al. 1992 [99] 0.7 20 (6–15) 6 weeks Imipramine Global improvement 4/9 (44%) No
Simeon et al. 1992 [100] 0.43 30 (M=11.8) 4 weeks Alprazolam CGI#2 5/13 (38%) No
Rynn et al. 2001 [101] 0.93 22 (5–17) 9 weeks Sertraline CGI#2 1/11 (9%) Yes
RUPP 2001 [102] 0.82 128 (6–17) 8 weeks Fluvoxamine CGI#2 19/65 (29%) Yes
Birmaher et al. 2003 [103] 0.89 74 (7–17) 12 weeks Fluoxetine CGI#2 13/37 (35%) Yes
Wagner et al. 2004 [104] 0.95 322 (8–17) 16 weeks Paroxetine CGI#2 59/154 (38%) Yes
Rynn et al. 2007 [105] 0.82 323 (6–17) 8 weeks Venlafaxine CGI#2 77/159 (48%) Yes
March et al. 2007 [106] 0.95 293 (8–17) 16 weeks Venlafaxine CGI#2 54/148 (37%) Yes
*and Boulos et al, 1992; **and Berard et al, 2006;
apossible superiority of drug vs placebo concerns the primary variable;
bthese reports are pooled analysis in which individual trials did not reveal significant treatment effect
N=number of subjects randomized in the study; Q=quality score of the report; CDRS: Children’s Depression Rating Scale; CGI: Clinical Global Impression-Severity;
HDRS: Hamilton Depression Rating Scale; K-SADS-dep: Schedule for Affective Disorder and Schizophrenia-depression/anhedonia subscore; MADRS: Montgomery-Asberg
Depression Rating Scale; CYBOCS: Child Yale-Brown Obsessive Compulsive Scale. Placebo responders: N of responders in the placebo arm/N of subjects randomised in
the placebo arm (%)
doi:10.1371/journal.pone.0002632.t001
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MDD, 31% (range: 4–41%) for OCD, and 39.6% (range: 9–53%)
for AD-non-OCD, with 1528, 371, and 634 children and
adolescents included in placebo arms, respectively. The analysis
conducted on the subgroup of studies (N=30) that used the CGI
to indicate responder status, yielded comparable results (F=15.1,
df=2, p,0.001).
Children showed a non-significantly higher placebo response
compared to adolescents (t value=1.12, p=0.27). Of note, (i) only
567 children and 1171 adolescents were included in these
secondary analyses due to lack of detailed data in many reports,
and (ii) the differences between pooled response rates was stable
across the three diagnoses ranging between 5 and 10%: 60%,
40%, and 42% of children with MDD, OCD, and AD-non-OCD
were placebo responders compared to 49%, 32%, and 32% of
adolescents with MDD, OCD, and AD-non-OCD. Figure 3 shows
placebo response rates as a function of the date of publication for
MDD, OCD and AD-non-OCD in children and adolescents.
Spearman rank correlations showed that there were no significant
correlations between placebo response and time of publication for
MDD and OCD [r=0.11 and r=0.1, respectively]. A negative
correlation was found between placebo response rate in AD-non-
OCD and time of publication [r=20.45, p=0.186]. This result
was not statistically significant; further, there was only one study
from the seventies including 19 patients, and one aberrant study
with a very low response rate including 11 patients.
Discussion
The current study shows that response to placebo differs among
internalized disorders in children and adolescents. Compared to
anxiety disorders including OCD, MDD appears to respond better
Figure 1. Trial flow of the pooled-analysis of placebo-response
in RCTs for internalized disorders in children and adolescents
(RCT: Randomized controlled trials; PBO: placebo).
doi:10.1371/journal.pone.0002632.g001
Figure 2. Placebo response rates (%) in trials for children and adolescents with major depressive disorder (MDD, number of
trials=23), obsessive compulsive disorder (OCD, number of trials=7), and other anxiety disorders (AD-non-OCD, number of
trials=10). ANOVA: F=7.1, df=2, p=0.002. N=total number of youths included in the placebo arms; PBO=Placebo.
doi:10.1371/journal.pone.0002632.g002
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medication. This is evidenced for both children and adolescents,
and is not influenced by response over time. The main limitation
of this study is the fact that we pooled all placebo arms from
studies that varied in their methodologies (e.g. inclusion criteria,
initial placebo washout period, definition of responders, and
duration of treatment). However, several positive points should be
kept in mind. First, in contrast to what has been shown in adult
mood disorders [22–24], we did not find a correlation between
placebo response rate and year of publication despite apparent
variability in both placebo rates and publication dates. Second,
age did not show any major influence on placebo response rates in
children and adolescents. Third, most of the data used in these
analyses came from studies on SSRIs that were conducted in the
late nineties and early 2000s, after several consensus conferences
and guidelines had been done on youth psychopharmacological
trials. Therefore, the methodologies were very similar for these
studies [6,30]. Fourth, when CGI was used to define placebo
response rates (either as primary or secondary variables), we
obtained the same results. As a consequence, we consider the
current results to have validity, and feel that they might reflect
differential psychopathology between MDD and anxiety disorders.
Other limitations should also be noted: (1) most of the studies were
sponsored by drug industry, and, in many studies, broad inclusion
criteria were used (e.g., including youths with comorbid anxiety in
depression trials and vice versa; excluding suicidal youths from
depression trials); (2) Pooled analysis does not address the fact that
MDD is likely to be highly heterogeneous and that some patients
may differ in their response to non-specific professional attention
(as evidenced in the wide range of placebo response rate across
studies, Figure 2); (3) Three studies conducted before 1980 did not
use DSM-III (or greater) criteria and may have had substantial
differences in the disorders’ definitions. However, they only
accounted for 48 patients total to analyses.
It is not in the scope of this paper to carefully review the main
psychological theories regarding MDD, OCD, and AD-non-
OCD. However, given that children and adolescents with MDD
appear to be more responsive to placebo than other youths with
internalized conditions, highlighting differential psychopathology
(a point called pharmaceutical dissection), may help with the
formulation of hypotheses about this pattern. Table 2 summarizes
the different theoretical views according to psychoanalytic theory,
cognitive/behavioral theory, and family/systems theory. The
following factors appear to clearly differentiate depression from
anxiety disorders in all three theoretical views. First, whether it is
called self-esteem or narcissism, a child needs to encounter positive
experiences of love, particularly in interactions with his early
caregivers, that may help him construct more self-confidence or a
stronger sense of self during development. Second, when this does
not occur, such as when early life adversities occur, the child
becomes vulnerable to a variety of loss experiences that he may
encounter in everyday life. Third, this vulnerability to loss
manifests in a specific search for adult recognition, care, and love
as it may restore the negative views on himself. Fourth, fear is the
main emotional dimension in AD, but does not appear much in
theories about the psychopathology of depression, unless depres-
sion is secondary to, and comorbid with, an AD [61]. On the
contrary, when loss is involved in the psychopathology of an AD, it
is at the level of threatened loss of the object-relationship, and not
at the level of real experiences of loss [62]. Several empirical
studies support these distinctions. Loss events are significantly
more prevalent among MDD than AD, both in youth [63] and in
adults [64]. Furthermore, the importance of early life adversities
distinguishes youth MDD from adult MDD [9].
Despite the limitations cited previously, several speculations can
be made to explain why placebo response rates are higher in
juvenile MDD than in anxiety disorders. When entering a double-
blind placebo-controlled trial, many aspects of the patient’s
psychosocial background are considered, since they may account
for treatment outcome, compliance, and protocol acceptance.
Whether intended or not, the clinician’s intervention may aid in
restoring self-esteem or narcissism in the depressed child or
adolescent. Furthermore, the intervention may encourage open-
ness to transference movements that may be intense at the first
meeting, and provide a ‘‘positive mirror’’ [7]. Indeed, the
formation of a therapeutic alliance is essential to the child’s
participation in a research efficacy trial. The trial protocol with its
frequent and regular meetings offers the child a unique
opportunity to restore his feelings of self-esteem and confidence
in the adult world, resulting in an unintentional psychotherapeutic
dynamic irrespective of the orientation of the clinician. We
hypothesize that this phenomenon may partially explain the
higher placebo response in youth MDD as compared to other
internalized disorders. Alternative hypotheses are also valid. First,
in addition to more classical common factors (such as therapeutic
relationship, a patient’s expectation of help, and treatment rituals),
Frank’s proposal that all psychotherapies have the shared feature
of reducing demoralization may also be claimed [65]. Frank stated
Figure 3. Placebo response rates in placebo-controlled parallel
trials as a function of time of publication for major depressive
disorder (MDD), obsessive compulsive disorder (OCD) and
other anxiety disorders (AD-non-OCD) in children and adoles-
cents. PBO=Placebo.
doi:10.1371/journal.pone.0002632.g003
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courage, powerlessness to mastery, and demoralizing meanings to
favorable ones. Youth with MDD may be more sensitive to
support and interest as well as more demoralized than individuals
with anxiety disorders; therefore, they may be more sensitive to
this aspect of treatment. Second, the high placebo response rates
found in child and adolescent depression can also be discussed in
terms of the practical significance of clinical trials. Double-blind
placebo-controlled trials are based on the assumption that drug
effects and placebo effects are additive. The high placebo response
rates in youth MDD that lead to small drug/placebo differences,
have called into question the validity of the assumption of
additivity. In this case, antidepressant drugs have substantial
pharmacological effects that are either duplicated or masked by
placebos [66]. Alternative methods of clinical trials should be
developed to test models other than additive ones. Third, it is
possible that some children and adolescents included in the
pharmaceutical trials were not depressed given the broad criteria
used in many studies. Finally, we cannot exclude that differences
in placebo arms between disorders may reflect differences in the
probability of spontaneous improvement. Most data regarding the
natural history of MDD, however, do not support this hypothesis
as MDD in children and adolescents appears to be a chronic and
disabling condition [1,8].
To summarize, MDD in children and adolescents appears to be
more responsive to placebo conditions than do other internalized
disorders, highlighting differential psychopathology. We hypoth-
esize that a non-specific response, through an unintentional
psychotherapeutic process, occurs in the placebo arms of double-
blind placebo-control trials, and that this non-specific response is
higher in child and adolescent MDD.
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development, they become pathological. The
family becomes involved in patterns of
interaction that maintain the child’s compulsive
behaviours via socialization, interpersonal
processes, and emotional regulation within the
family group. Symptom-maintaining patterns of
interaction may also meet their needs.
AD-non-OCD Defence mechanisms are used to keep
unacceptable impulses or sexual thoughts from
entering consciousness. These unacceptable
feelings and related moral anxiety are displaced
onto a phobic object or onto all available objects.
Anxiety occurs when life events involving
threat reactivate threat-oriented cognitive
schemas formed in childhood during stressful
experiences. These schemas contain
assumptions about the dangerous nature of
the environment or the child’s health. Notably,
when loss is involved it is at the level of
threatened rather than actual loss.
Family lifecycle transitions or stressful events
precipitate the onset of anxiety disorders, which
are maintained by patterns of interaction where
anxiety is reinforced. Moreover, parental child-
focused behaviour may serve to allow parents to
avoid marital and personal issues.
For anxiety disorders in children, attachment theory proposes an attempt to integrate various theoretical aspects. This theory supports a relationship
between behavioural inhibition, insecure mother-child attachment, and evidence of anxiety in the offspring of mothers with anxiety disorders.
Adapted from Manassis et al, 1997 [107]; Flament and Cohen, 2004 [108]; Marcelli and Cohen, 2006 [109]; Carr, 1999 [110].
MDD=Major Depressive Disorder; OCD=Obsessive Compulsive Disorder; AD-non-OCD=Anxiety Disorder other than OCD and Post Traumatic Stress Disorder.
doi:10.1371/journal.pone.0002632.t002
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